Treatment of blastomycosis

Current Fungal Infection Reports

Volumn 4, Issue 1, 2010, Pages 23-29

  Proia, Laurie A ^a  

^a NONE

Author keywords

Blastomyces dermatitidis; Blastomycosis; Endemic mycosis or endemic fungal infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADULT RESPIRATORY DISTRESS SYNDROME; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CEREBROSPINAL FLUID ANALYSIS; DRUG BIOAVAILABILITY; ENZYME IMMUNOASSAY; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; NONHUMAN; PATIENT EDUCATION; REVIEW; STOMACH ABSORPTION; SYNOVIAL FLUID; THORACOTOMY; TREATMENT DURATION;

EID: 79952189699     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-010-0003-0     Document Type: Review

References (50)

1. Sarosi GA, Davies SF: Blastomycosis: state of the art. Am Rev Respir Dis 1979, 120:911-938.
2. Dworkin MS, Duckro AN, Proia L, et al.: The epidemiology of blastomycosis in Illinois and factors associated with death. Clin Infect Dis 2005, 41:e107-e111.
3. Vasquez JE, Mehta JB, Agrawal R, Sarubbi FA: Blastomycosis in northeast Tennessee. Chest 1998, 114:436-443. (Pubitemid 28387520)
4. Reed KD, Meece JK, Archer JR, Peterson AT: Ecologic niche modeling of Blastomyces dermatitidis in Wisconsin. PLOS One 2008, 3:e2034.
5. Witorsch P, Utz JP.: North American blastomycosis: a study of 40 patients. Medicine 1968, 47:169-200.
6. Manetti AC: Hyperendemic urban blastomycosis. Am J Pub Health 1991, 81:633-636.
7. Dwight PJ, Naus M, Sarsfield P, Limerick B: An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora catchment region of Ontario, Canada. Can Commun Dis Rep 2000, 26:82-91.
8. Bradsher RW: Pulmonary blastomycosis. Semin Respir Crit Care Med 2008, 29:174-181. This excellent review article on blastomycosis is written by one of the leading authorities in infectious diseases.
9. Pappas PG, Threlkeld MG, Bedsole GD, et al.: Blastomycosis in immunocompromised patients. Medicine (Baltimore) 1993, 72:311-325. (Pubitemid 23360478)
10. Pappas PG, Pottage JC, Pottage JC, et al.: Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992, 116:847-853. (Pubitemid 23034764)
11. Gray NA, Baddour LM: Cutaneous inoculation blastomycosis. Clin Infect Dis 2002, 34:E44-E49.
12. Klein BS, Vergeront JM, Weeks RJ, et al.: Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. New Engl J Med 1986, 314:529-534. (Pubitemid 16128059)
13. Crampton TL, Light RB, Berg GM, et al.: Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis 2002, 34:1310-1316.
14. Miller DD, Davies SF, Sarosi GA: Erythema nodosum and blastomycosis. Arch Intern Med 1982, 142:1839. (Pubitemid 12036219)
15. Meyer KC, McManus EJ, Maki DG: Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N Engl J Med 1993, 329:1231-1236. (Pubitemid 23306324)
16. Chapman SW, Lin AC, Hendricks KA, et al.: Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect 1997, 12:219-228. (Pubitemid 27411205)
17. Crampton TL, Light RB, Berg GM: Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis 2002, 34:1310-1316. (Pubitemid 34507939)
18. Cherniss EI, Waisbren BA: North American blastomycosis: a clinical study of 40 cases. Ann Intern Med 1956, 44:105-123.
19. Kaplan W, Clifford MK: Blastomycosis I: a review of 198 collected cases in veterans administration hospitals. Am Rev Respir Dis 1964, 89:659-672.
20. Gauthier GM, Safdar N,Klein BS,AndesDR: Blastomycosis in solid organ transplant recipients. Transpl Infect Dis 2007, 9:310-317. (Pubitemid 350059144)
21. Oppenheimer M, Embil JM, Black B, et al.: Blastomycosis of bones and joints. South Med J 2007, 100:570-578. (Pubitemid 46956538)
22. Inoshita T, Youngberg GA, Boelen LJ, Langston J: Blastomycosis presenting with prostatic involvement: report of 2 cases and review of the literature. J Urol 1983, 130:160-162. (Pubitemid 13074095)
23. Murray JJ, Clark CA, Lands RH: Reactivation blastomycosis presenting as a tubo-ovarian abscess. Obstet Gynecol 1984, 64:828-830. (Pubitemid 15219432)
24. Bariola J, Perry P, Pappas P, et al.: Central nervous system blastomycosis: review of recent experience. Clin Infect Dis 2009, In press.
25. Merz WG, Roberts GD: Algorithms for detection and identification of fungi. In Manual of Clinical Microbiology. Edited by Murray PR. Washington, DC: ASM Press; 1999:1167-1183.
26. Vyas KS, Bariola JR, Bradsher RW: Advances in the serodiagnosis of blastomycosis. Curr Fung Infect Rep 2008, 2:227-231. This is a comprehensive review of methods for diagnosing blastomycosis.
27. Wheat J, Wheat H, Connolly P, et al.: Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997, 24:1169-1171. (Pubitemid 27249019)
28. Durkin M, Witt J, LeMonte A, et al.: Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol 2004, 42:4873-4875. (Pubitemid 39362430)
29. Chapman SW, Dismukes WE, Proia LA, et al.: Clinical practice guidelines for the management of blastomycosis: 2008 Update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:1801-1812. This is a must-read for any clinician who treats patients with blastomycosis.
30. Dismukes WE, Bradsher RW, Cloud GC, et al.: Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992, 93:489-497.
31. Itraconazole [package insert]. Ortho-McNeil-Janssen Pharmaceuticals; 2008.
32. Barone JA, Koh JG, Bierman RH, et al.: Food interaction and steady state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993, 37:778-784. (Pubitemid 23096878)
33. Stein AG, Daneshmend TK, Warnock DW, et al.: The effects of H2-receptor antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br J Clin Pharmacol 1989, 27:105-106.
34. Jaruratanasirikul S, Sriviriyajan S: Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998, 54:159-161. (Pubitemid 28204270)
35. Barone JA, Moskovitz BL, Gaurnieri J, et al.: Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998, 42:1862-1865. (Pubitemid 28311595)
36. Saad AH, DePestel DD, Carver PL: Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006, 26:1730-1744. (Pubitemid 44885328)
37. Li RK, Ciblak MA, Nordoff N, et al.: In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000, 44:1734-1736.
38. Poirier M, Cheymol G: Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998, 35:461-473.
39. Wong-Beringer A, Jacobs RA, Guglielmo BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998, 27:603-618. (Pubitemid 28422013)
40. Groll AH, Giri N, Petraitis V, et al.: Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182:274-282. (Pubitemid 30497814)
41. Pappas PG, Bradsher RW, Chapman SW, et al.: Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1995, 20:267-271.
42. Espinel-Ingroff A: Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998, 36:2950-2956.
43. Sugar AM, Liu XP: Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother 2001, 45:601-604. (Pubitemid 32105301)
44. Sugar AM, Liu XP: In vitro and in vivo activities of SCH56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996, 40:1314-1316.
45. Johnson LB, Kauffman CA: Voriconazole: a new triazole antifungal. Clin Infect Dis 2003, 36:630-637.
46. Pascual A, Calandra T, Bolay S: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46:201-211. (Pubitemid 351269158)
47. Freifeld A, Proia L, Andes D, et al.: Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009, 53:1648-1651.
48. Lutsar I, Roffey S, Troke P: Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003, 37:728-732. (Pubitemid 37100817)
49. Nagappan V, Deresinski S: Posaconazole: a broad spectrum triazole antifungal agent. Clin Infect Dis 2007, 45:1610-1617. (Pubitemid 351411847)
50. Smith JA, Kauffman CA: Endemic fungal infections in patients receiving tumor necrosis factor-alpha inhibitor therapy. Drugs 2009, 69:1403-1415.